Blue-light based Cardiac rejuvenation therapy: Exposure to intense blue light suppresses tumor suppressor INK4a/p16 expression and inhibits dilated cardiomyopathy, via upregulation of its target gene, 27/November/2018, 10.28 am

 Molecular therapy for safeguarding your heart against cardiac dysfunction: Prostaglandin E2(PGE2)/Dinoprostone  (trade name: Cervidil, Propess, and others), the drug used to induce labor and in others,  decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 27/November/2018, 10.10 am
November 27, 2018
Laminar shear stress-based therapy for autoimmune diabetes (TIDM): Laminar shear stress increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 27/November/2018, 11.25 am
November 27, 2018
Show all

What we say:

Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Blue-light based Cardiac rejuvenation therapy: Exposure to intense blue light suppresses tumor suppressor INK4a/p16 expression and inhibits dilated cardiomyopathy, via upregulation of its target gene


From the Significance of the study to Public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) Dilated cardiomyopathy is the leading cause of Heart failure; (3) the raise  of death rate, due to cardiovascular disease, has increased from 12.3 million in 1990 to 17.3 million in 2013; (4) 13% of cardiovascular disease occur due to  uncontrolled high blood pressure; (5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) 85% of people over  80 years are susceptible to cardiovascular diseases; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; and (9) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find:  (i) a cure to diseases, as mentioned above, leading to cardiovascular disease; (ii) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (iii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From research findings to therapeutic opportunity:  

This study suggests, for the first time, that exposure to intense blue light, by increasing the expression of its target gene, it may increase the expression of oncoprotein BMI-1 and suppress the expression of tumor suppressor and the aging marker INK4a/p16 (figure 1 ) in cardiomyocytes.

[easy_payment currency=”USD”]

Figure 1. Mechanistic insight into exposure to intense blue light may function as a cardioprotective agent. Exposure to intense blue light  inhibits dilated cardiomyopathy and heart failure, via down-regulation of aging/senescence marker INK4a

Figure 2. Exposure to intense blue light protects against cardiac myopathy through down-regulation of tumor suppressor INK4a

 

Thereby, it may: (1) inhibit cardiac senescence; (2) increase of regenerative potential in aged tissues; and (3) improve ventricular dimensions and contractility.

Thus, (1) by exposing myocardial patients with blue light , one may prevent Dilated  cardiomyopathy and ageing-associated (or, stress-associated) decline in cardiac function; and (2) blue light-based treatment, either alone or in combination with any of the known cardioprotective drugs” may be used to inhibit dilated cardiomyopathy and heart failure (figure 1).

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does blue light decrease the expression of tumor suppressor INK4a?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L., Blue-light based Cardiac rejuvenation therapy: Exposure to intense blue light suppresses tumor suppressor INK4a/p16 expression and inhibits dilated cardiomyopathy, via upregulation of its target gene, 27/November/2018, 10.28 am, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.